Open, Two-stage, Multicenter, Monotherapy, Phase II Clinical Study of Utidelone Injection in Patients With Advanced or Metastatic Solid Tumors After Failure or Intolerability to Standard Treatment

Beijing Biostar Pharmaceuticals Co., Ltd.3 个研究点分布在 1 个国家目标入组 120 人开始时间: 2021年1月22日最近更新: 2023年11月8日

适应症

干预措施

试验速览

阶段: 2 期
状态: 招募中
发起方: Beijing Biostar Pharmaceuticals Co., Ltd.
入组人数: 120
试验地点: 3
主要终点: Tumor response to utidelone treatment

研究概览研究设计入排标准研究组 & 干预措施结局指标研究者研究点记录与标识符相似试验

研究概览

简要总结

This trial is an open, two-stage, multi-center, phase II clinical trial to evaluate the efficacy and safety of Utidelone in advanced solid tumors (excluding breast cancer, lung cancer, and colorectal cancer) that have failed standard of treatment or were unable to perform standard treatment.

This trial is divided into 2 stages, screening stage and expansion stage. In the screening stage, 10 patients were enrolled for each tumor type(including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors). Based on the results of the tumor type screening stage, the sponsor and the main investigator will have a discussion and have the alignment of tumor types to enter the expansion stage. The expansion stage will refine the inclusion / exclusion criteria and may adjust the treatment plan based on the tumor type and the combination drug selection. A total of 30-50 patients (including patients enrolled in the screening stage) were enrolled in each specified tumor type during the expansion stage.

研究设计

研究类型: Interventional
分配方式: Non Randomized
干预模型: Parallel
主要目的: Treatment
盲法: None

入排标准

年龄范围: 18 Years 至 75 Years（Adult, Older Adult）
性别: All
接受健康志愿者: 否

入选标准

•Histologically or cytologically documented locally-advanced and/or metastatic solid malignancy (including Squamous cell carcinoma of head and neck, Esophageal cancer, Stomach cancer, Pancreatic cancer, Cholangiocarcinoma, Ovarian cancer and Other solid tumors) that is incurable, and has failed prior standard therapy or for which standard therapy is not appropriate.
•Have measurable disease based on Response Criteria in Solid Tumors Version 1.1 (RECIST 1.1)
•Age 18 -70 years old
•ECOG performance status of 0-1
•Life expectancy≥ 3 months
•Basically normal results from routine blood test within 1 week prior to enrollment
•Absolute neutrophil count (ANC) >= 1.5 x 10^9/L
•Hemoglobin >= 9 g/dL
•Platelets >= 80 x 10^9/L
•Basically normal liver and renal functions within 1 week prior to enrollment
•total bilirubin =< 1.5 x ULN with direct bilirubin within normal range
•Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 3 x ULN (ALT and AST =< 5 x ULN is acceptable if liver metastases are present)
•Creatinine clearance>=50 ml/min
•Women and men of childbearing potential must agree to take effective contraceptive measures during the study and within six months after the last treatment. Female patients must have negative urinary pregnancy test within 7 days before the first treatment (postmenopausal women must have no menstruation for at least 12 months before they are considered unable to conceive)
•Patients who give written informed consent with good compliance.

排除标准

•Received chemotherapy, radiotherapy, biological therapy, endocrine therapy, immunotherapy and other anti-tumor treatments within 4 weeks prior to enrollment while participating in this trial, except for the following items:
•Nitrosourea or mitomycin C is within 6 weeks before the first dosage of the study drug;
•Oral fluorouracil and small molecule targeted drugs are 2 weeks before the first use of the study drug or 5 half-life periods of the drug (whichever is longer);
•The traditional Chinese medicine with anti-tumor indication is within 2 weeks before the first use of the research medicine.
•Received other unlaunched clinical research drugs or treatment within 4 weeks before the first dosage of the research drug.
•Have undergone major organ surgery (excluding needle biopsy) or experienced significant trauma within 4 weeks prior to the first dosage of study drug, or require elective surgery during the trial period.
•Symptomatic peripheral neuropathy CTCAE 5.0 grade evaluation ≥ grade 2
•With severe allergies to castor oil, or have had serious adverse reactions with anti-microtubule drugs in the past
•Patients of pregnancy or breast feeding
•Patients with AEs caused by any previous treatment (including systemic and local treatment) that have not yet restored to GRADE 1 (excluding hair loss)
•Patient with known active central nervous system (CNS) metastases and/or carcinomatous meningitis.
•Patients with active infections and currently need systemic anti-infective treatment
•Patient with immunodeficiency, including a positive HIV antibody test.
•Patients with history of active hepatitis B (hepatitis B virus titer> ULN), allow prophylactic antiviral treatment other than interferon; have a history of hepatitis C virus infection (hepatitis C antibody positive).
•Patients with history of serious cardiovascular and cerebrovascular diseases.
•Patients with mental disorders or patients with poor compliance.
•Patients not fitted for this study determined by the investigators.

研究组 & 干预措施

Squamous cell carcinoma of head and neck: Utidelone Injection

Experimental

Cohort 1 Squamous cell carcinoma of head and neck. Participants will be treated with utidelone monotherapy